NeoGenomics, Inc. reported a revenue increase of 10.1% for the fiscal year ended December 31, 2025, reaching $727.3 million compared to $660.6 million in 2024. The growth was attributed to higher test volumes, a shift towards more valuable tests, and the positive impact of strategic reimbursement initiatives. However, the company also experienced a net loss of $108 million, widening from a loss of $78.7 million in the previous year. This increase in losses was influenced by higher costs associated with revenue, which rose by 11.5% to $413 million, primarily due to increased compensation, supplies, and shipping expenses.

In 2025, NeoGenomics completed the acquisition of Pathline, a laboratory based in New Jersey, for an initial cash consideration of $8 million, with potential contingent payments of up to $2 million based on performance milestones. This acquisition is expected to enhance the company's capabilities and market presence in the Northeastern United States. Additionally, the company resolved ongoing patent litigation related to its RaDaR ST test, which contributed to a more favorable operational outlook.

Operationally, NeoGenomics reported a total employee count of approximately 2,500 as of December 31, 2025, including contracted pathologists. The company operates a network of laboratories across the U.S. and the U.K., with a focus on oncology diagnostic testing. The company’s strategic initiatives for 2026 include expanding its community oncology market presence, enhancing customer experience, and driving innovation in precision diagnostic testing solutions.

Looking ahead, NeoGenomics aims to sustain its growth trajectory by investing in advanced molecular testing and expanding its test menu. The company plans to focus on operational efficiency through automation and process improvements while maintaining a commitment to quality service. Despite the challenges posed by increased competition and regulatory scrutiny, NeoGenomics remains optimistic about its future prospects in the oncology diagnostics market.

About NEOGENOMICS INC

NeoGenomics, Inc. specializes in oncology diagnostic testing and consultative services, including molecular, cytogenetic, and histopathology analyses. Operating laboratories in the U.S. and U.K., it serves healthcare providers, pharmaceutical companies, and research institutions. The company offers comprehensive cancer testing, interpretation, and data solutions, leveraging advanced technologies like NGS and liquid biopsies to support personalized medicine and drug development. Its core focus is improving patient outcomes through high-quality, innovative cancer diagnostics.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.